In Hatten v. Grobet United States, the U.S. District Court for the District of Arizona recently ruled on a defendants motion to remove the case to federal court. In this case, plaintiff Renee Hatton alleged that as a result of the defendants actions, her mother contracted mesothelioma from exposure to asbestos-containing products between 1977 and 1979 while working as an art teacher and jewelry-making instructor at Fort Huachuca. Defendant Grobet filed a notice of removal, asserting that the court had federal enclave jurisdiction, as well as diversity jurisdiction over the suit.

The plaintiff argued the case should be remanded because the defendants notice of removal was procedurally defective in that it failed to include proof of consent of all defendants, because one defendant was an Arizona resident defeating diversity jurisdiction, and that the court did not have federal enclave jurisdiction. Defendant Grobet argued the Arizona defendant was fraudulently joined in the case, thus justifying diversity jurisdiction. The court ultimately disagreed that the Arizona defendant was fraudulently added to the case. Therefore, the court found that Grobet failed to establish diversity jurisdiction over this case. The court also dismissed Grobets federal enclave jurisdiction argument. Specifically, the court found Grobet could not establish that the federal government possessed an exclusive interest over Fort Huachuca.

As a result of Grobets failure to establish a basis to support federal jurisdiction, and that the acts at issue in this case occurred on a federal enclave subject to exclusive federal jurisdiction, the court remanded the case for further proceedings.

Read the original here:

Case Remanded to State Court Due to Lack of Diversity or Federal Enclave Jurisdiction Over Equipment Manufacturer - Lexology

In rare cases, mesothelioma cancer may metastasize (spread) to the patients brain. Mesothelioma often begins in the lungs, abdomen or heart after exposure to asbestos. Mesothelioma is a rare disease, accounting for only 0.19% of new cancer diagnoses from 2013 to 2017.

Mesothelioma metastasis to the brain is unlikely. Brain metastasis occurs in only about 3% of mesothelioma patients. Some studies analyze the prevalence of mesothelioma in the brain. They provide insight into how it occurs and potential treatment options.

Though rare, mesothelioma may spread to the brain. A 2016 study from researchers at Okayama Rosai Hospital studied 150 malignant pleural mesothelioma (MPM) patients. The researchers found eight patients, or 5.3%, developed brain metastasis.

A study by Australian and British researchers found a lower likelihood of brain metastasis, at 3%. The study confirmed mesothelioma is more likely to metastasize to other areas first. Around 87.7% of MPM patients had metastasis sites somewhere in the body. According to this research, mesothelioma is more likely to spread to the lymph nodes and chest cavity.

Metastasis to the brain can occur when cancer cells spread:

The lymphatic system is a network of lymph nodes that filter waste from the body. Cancerous cells may reach the lymph nodes and collect there. If this happens, metastasis in the lymph nodes can occur.

From the lymphatic system, cancer can cross into the bloodstream and enter the circulatory system. Once mesothelioma cells are in the bloodstream, they can cross the blood-brain barrier. The cells can then spread to the brain and lead to tumor development.

Symptoms reported by mesothelioma patients with brain metastasis include:

These symptoms differ from common mesothelioma symptoms. Patients experiencing any of these symptoms should contact their doctor immediately. In some cases, individuals may not experience these symptoms, even with brain metastasis.

One study identified age and cancer stage as common factors among patients with brain metastasis. This study was done by the Okayama Rosai Hospital.

The study found patients over the age of 65 and in stage four of mesothelioma were most likely to have brain metastasis. These factors show brain metastasis is most likely in patients who have lived with mesothelioma for a while. There are no documented cases of brain metastasis appearing first in mesothelioma patients.

The longer a patient lives with untreated mesothelioma, the more likely they are to have brain metastasis. Treating localized mesothelioma first may prevent metastasis.

Due to the rarity of brain metastasis in mesothelioma patients, few patients have received treatment. Patients with brain metastasis are often in late stages of cancer. As a result, they may prefer to treat the symptoms rather than remove the tumors.

Early diagnosis and treatment before metastasis are the best ways to prevent brain tumors.

However, there are three potential treatment options for mesothelioma brain metastasis. This includes surgery, chemotherapy and dexamethasone.

These treatments may help patients with mesothelioma brain metastasis. However, metastasis to the brain is very rare in this cancer. More research is needed to study treatment effectiveness. If you or a loved one with a mesothelioma diagnosis experiences these symptoms, contact your doctor.

Follow this link:

Does Mesothelioma Spread to the Brain? - Mesothelioma.com

(MENAFN - EIN Presswire)

JACKSON, MISSISSIPPI , USA, July 30, 2020 / EINPresswire.com / -- The Mississippi Mesothelioma Victims Center says, "We are urging the wife, adult son-daughter or a loved one of a Navy Veteran who has just been diagnosed with confirmed mesothelioma in Mississippi to please call 800-714-0303 for direct access to attorney Erik Karst of the law firm of Karst von Oiste. Mesothelioma compensation for a Navy Veteran can frequently exceed a million dollars-if the lawyers representing the person with this rare cancer caused by asbestos exposure know what they are doing. Erik Karst is one of the nation's most experienced mesothelioma attorneys and he knows what he is doing when it comes to mesothelioma compensation for Navy Veterans and people with this rare cancer caused by asbestos exposure.

"We do not want a Navy Veteran or person with mesothelioma in Mississippi rolling the dice on their compensation. Before you retain the services of a lawyer to assist with mesothelioma compensation please call Erik Karst of the law firm of Karst von Oiste at 800-714-0303. Erik and his colleagues at the law firm of Karst von Oiste have been assisting Navy Veterans and people with mesothelioma for decades and they are responsible for over a billion dollars in financial compensation individuals like this. Attorney Erik Karst of Karst von Oiste is a much better deal than a 'free' booklet about mesothelioma." [To enable links contact MENAFN]

Important Note from the Mesothelioma Victims Center: "If your loved one is a Navy Veteran, or person over 60 years old and you know he a had significant exposure to asbestos in the navy or at work prior to 1982-please tell the doctors who are treating him about the asbestos exposure-if he is now in the hospital with suspected Coronavirus-COVID-19." [To enable links contact MENAFN]

For the best possible mesothelioma treatment options in Mississippi the Mississippi Mesothelioma Victims Center strongly recommends the following heath care facility with the offer to help a diagnosed victim, or their family get to the right physicians at this hospital:

* University of Mississippi Medical Center Jackson, Mississippi: [To enable links contact MENAFN]

The Mississippi Mesothelioma Victims Center's initiative is a service available to any diagnosed victim of mesothelioma throughout Mississippi in every community such as Jackson, Gulfport, Southaven, Hattiesburg, Biloxi, and Tupelo. [To enable links contact MENAFN]

High risk work groups for exposure to asbestos in Mississippi include Veterans of the US Navy, power plant workers, shipyard workers, oil refinery workers, factory workers mill workers, plumbers, electricians, welders, auto mechanics, machinists, and construction workers. Typically, the exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. [To enable links contact MENAFN]

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. However, mesothelioma does happen in Mississippi.

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: [To enable links contact MENAFN] .

Michael ThomasMississippi Mesothelioma Victims Center+1 800-714-0303email us here

Visit link:

Mississippi Mesothelioma Victims Center Urges the Family of a Navy Veteran with Recently Diagnosed Mesothelioma in Mississippi to Please Call Attorney...

Global Mesothelioma treatment Market presents an in-depth review and technical research, with useful facts and figures, of the current and future state of the mesothelioma treatment market worldwide. mesothelioma treatment market provides information on emerging market opportunities and business factors, developments and evolving technologies that will fuel these growth trends. The report provides a comprehensive overview including Comparison of Definitions, Range, Use, Production and CAGR (percent), Form Segmentation, Share, Revenue Status and Outlook, Capacity, Demand, Market Drivers, Production Status, and Outlook and Opportunities, Export, Import, Growth Rate for Emerging Markets / Countries. The study provides a 360-degree overview of the industrys competitive landscape. The industry study on mesothelioma treatment assesses the main regions (countries) promising a huge market share for the 2016-2028 forecast period.

The market research study on mesothelioma treatment was collected through comprehensive primary research through interviews, surveys, and findings of experienced analysts and secondary research. The study also provides a complete qualitative and quantitative assessment by analyzing data obtained from industry analysts and market participants from mesothelioma treatment around key points in the value chain of the industry.

The regional analysis of this report covers the following regions- Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Ono Pharmaceutical Co. Ltd, Bayer AG, Teva Pharmaceuticals Industries Ltd.

Get Sample Copy of The Report @ https://www.quincemarketinsights.com/request-sample-68793?utm_source=Kalpesh&utm_medium=BL

Useful findings of this research are-

-Study of historical data.

-Analysis of existing scenarios in every domestic and national sector.

-Study of patterns, accessible knowledge and data figures.

-Use of validated project methods for the next five years.

Statistical analysis, figures and prime data included in the report contains-

-Market size (current and projected for the last few years)

-Market share analysis as per different companies)

-Market forecast)

-Demand)

-Price analysis)

-Market contributions (Size, Share according to geographical boundaries)

The report benefits Market Investigators, companies, Vendors, Buyers, Suppliers, Individual professionals and Competitive organizations

Make An Enquiry Before Purchasing Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-68793?utm_source=Kalpesh&utm_medium=BL

Market Segmentation:

ByTreatment Type:

By Route of Administration:

ByDistribution Channel:

By End User:

By Region:

North AmericaMesothelioma treatment market

EuropeMesothelioma treatment market

Asia PacificMesothelioma treatment market

Middle East & AfricaMesothelioma treatment market

South AmericaMesothelioma treatment market

Contact:Quince Market InsightsOffice No-A109Pune, Maharashtra 411028Phone: +91-9850603687/7972869557Email: [emailprotected]Web: http://www.quincemarketinsights.com

About :QMI has the most comprehensive collection of market research products and services available on the web. Deliver reports from almost all major publications and update the list on a regular basis with instant online access to the worlds broadest and most up-to-date archive of expert insights on global markets, companies, products and patterns.

Read more from the original source:

Mesothelioma treatment Market Insight And Key Players With Forecasts Up To 2028 - Bulletin Line

I have been scrupulous about protecting myself from COVID-19. Mostly staying home, masking-up on those rare occasions when I have ventured out, hand-washing like an OCD patient, keeping social distance from friends and family. You know the drill.

Four-plus months of this, however, have begun to take their toll. Maintaining my physical health has started to do a job on my mental health. Some days I feel like Robinson Crusoe before Friday showed up.

I began thinking about the odds of my actually contracting COVID-19 and whether it might be OK to modify my routine a little. My thoughts turned to the evolutionary biologist, Stephen Jay Gould. In his 1996 book "Full House," Gould describes his reaction to being diagnosed with mesothelioma. He was in his early 40s at the time (1982). He knew the median survival for his type of cancer was just eight months, but he also knew that measures of central tendency like medians dont capture range or individual variation.

The median is the halfway point. Half of people with mesothelioma, he observed, may die within eight months, but the other half will live longer and some will live significantly longer. Gould assessed his personal odds of survival to be well above average. He was young, had been diagnosed early and had access to exceptional medical care. He lived another 20 years.

With Gould in mind, I started researching the average risk related to COVID-19. I know that we are safer living in Maine than we would be in Texas, Florida or Arizona. I also know that the risk of dying from COVID-19 is greater for people older than I and for those living in institutional settings. I began to wonder what other variables might affect personal risk. I came to understand that each persons risk is different from every other persons risk because risk hinges on a combination of factors particular to each of us.

You might start by determining the basic risk. The Cleveland Clinic has developed a tool to help you. Research conducted in Cleveland has shown that the risk of a positive result is lower, for example, for people who have received their pneumococcal vaccine or their influenza vaccination. Ive had both. Lower risk for me. Its also lower for people who take certain medications like ACE Inhibitors, which I dont take. Higher risk for me there.

You can access the Clinics online survey at riskcalc.org. On the site you enter your age, race, ethnicity, gender, zip code, medical history, etc. Press the "run calculator" button and the algorithm spits out your odds of testing positive for COVID-19. The Clinic makes clear that their tool is not intended for medical advice.

When I took the survey, I found my risk of getting a positive test was just under 7.5% or about 1 in 13. This is much higher than the odds of being struck by lightening but a lot less than dying of coronary artery disease.

My relatively low level of risk made me curious about how the other factors identified in the Cleveland tool influence risk. I started playing around with the calculator. All other things being equal: what if I were a woman? Lower risk. What if I were Black or Hispanic? Higher risk. This underscores the central point: even though our collective risks are related, your risk is not my risk.

While I can calculate my own risk of contracting COVID-19, I have no way of knowing what yours might be. Only narcissists, fools or villains would dispense with all precautions just because their personal risk is low. What about the other guy?

Were all trying to find ways to live in relative safety. People have got to live their lives, but we can do that and still protect ourselves as well as those around us who are at greater risk from COVID-19. Go ahead and participate in lower-risk activities like cycling, going to the beach and al fresco dining, but think twice about higher risk activities like amusement parks, bar hopping and flying across country.

It is possible to protect your physical health without losing a grip on your mental health. Just dont throw all caution to the wind. By wearing a face covering in public, following the 6-foot rule and washing your hands, you can reduce the risk of infection for everyone.

Ron McAllister is a sociologist and writer who lives in York.

Here is the original post:

Assessing the risks: Mine, yours and ours - Seacoastonline.com

La Jolla, CA-based Inhibrx couldnt get their $75 million IPO over the goal line last year. But with the fervor for new biotech filings seemingly growing on Wall Street, they plan to see how a $100 million play will work out now.

This time around, Inhibrx touts four Phase I drugs in the pipeline developed on its single domain antibody (sdAb) platform, three of which are geared toward various cancers. The fourth drug, INBRX-101, targets Alpha-1 Antitrypsin Deficiency (AATD).

Our sdAb platform allows us to pursue validated targets with clinical promise, but where other antibody and biologic based approaches have failed. Highly modular, our sdAbs can be combined with precise valencies and multiple specificities, creating therapeutic candidates designed to be capable of enhanced cell signaling, conditional activation or combined synergistic functions, the latest SEC filing states.

Jefferies Group, Evercore ISI and Credit Suisse are the joint bookrunners on this years deal. In 2019, the biotech sold a convertible promissory note totaling $40 million to Viking Global Investors. This April, it raked in another $15 million in notes to Viking and other undisclosed investors. The notes will eventually settle into shares of the companys common stock.

Most of the companys revenue trickles in from grants, equity and debt financings, and license and milestone revenue, according to the filing. By June 30, the company had run through $107.2 million. As the result of a license deal the company struck with Celgene years before the Bristol Myers Squibb buyout, Inhibrx could stand to receive up to $934 million, plus royalties that range from the high single-digits to the low teens.

Currently, Inhibrxs most advanced drug in the pipeline is INBRX-109, a tetravalent candidate. The drug agonizes DR5, which Inhibrx says led to cancer cell death in preclinical studies. The company believes INBRX-109 could trigger cell death in a variety of cancers, including colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, mesothelioma and certain sarcomas.

The first part of a Phase I trial and dose escalation conducted in 2018 and 2019 respectively showed that the drug was well-tolerated, with no significant toxicities observed at doses up to and including the maximum administered dose of 30 mg/kg, according to the companys website.

The company is in the middle of Phase I Part 2, and currently has 75 patients enrolledwith colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, and chondrosarcoma. Initial data from the chondrosarcoma and malignant pleural mesothelioma patients should be ready by the end of the year.

Inhibrxs second drug in the pipeline, INBRX-106, is an OX40 hexavalent agonist. The first part of a Phase I trial was conducted in December, with data to come this year.

We believe INBRX-106, a hexavalent therapeutic candidate with the ability to bind six OX40 molecules per molecule of drug, has the potential to achieve improved receptor clustering and downstream signaling. In preclinical studies, we have observed that INBRX-106 mediated T-cell co-stimulation and also reduced the suppressive activity of regulatory T-cells, with superior activity to bivalent comparators, the SEC filing states.

The third of Inhibrxs oncology drugs, INBRX-105, could be used to treat those with PD-L1 expressing tumors. The drug agonizes 4-1BB, but only in the presence of PD-L1. Initial dose escalation data is coming in 2021, the company says.

INBRX-101 is a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD. The Phase I dose escalation trial was put on hold due to the Covid-19 pandemic, but should testing resume, Inhibrx could announce initial data in the second half of 2021.

See the rest here:

Inhibrx takes a second shot at an IPO this time bumping the goal to $100M-plus - Endpoints News

I have been scrupulous about protecting myself from COVID-19. Mostly staying home, masking-up on those rare occasions when I have ventured out, hand-washing like an OCD patient, keeping social distance from friends and family. You know the drill.

Four-plus months of this, however, have begun to take their toll. Maintaining my physical health has started to do a job on my mental health. Some days I feel like Robinson Crusoe before Friday showed up.

I began thinking about the odds of my actually contracting COVID-19 and whether it might be OK to modify my routine a little. My thoughts turned to the evolutionary biologist, Stephen Jay Gould. In his 1996 book "Full House," Gould describes his reaction to being diagnosed with mesothelioma. He was in his early 40s at the time (1982). He knew the median survival for his type of cancer was just eight months, but he also knew that measures of central tendency like medians dont capture range or individual variation.

The median is the halfway point. Half of people with mesothelioma, he observed, may die within eight months, but the other half will live longer and some will live significantly longer. Gould assessed his personal odds of survival to be well above average. He was young, had been diagnosed early and had access to exceptional medical care. He lived another 20 years.

With Gould in mind, I started researching the average risk related to COVID-19. I know that we are safer living in Maine than we would be in Texas, Florida or Arizona. I also know that the risk of dying from COVID-19 is greater for people older than I and for those living in institutional settings. I began to wonder what other variables might affect personal risk. I came to understand that each persons risk is different from every other persons risk because risk hinges on a combination of factors particular to each of us.

You might start by determining the basic risk. The Cleveland Clinic has developed a tool to help you. Research conducted in Cleveland has shown that the risk of a positive result is lower, for example, for people who have received their pneumococcal vaccine or their influenza vaccination. Ive had both. Lower risk for me. Its also lower for people who take certain medications like ACE Inhibitors, which I dont take. Higher risk for me there.

You can access the Clinics online survey at riskcalc.org. On the site you enter your age, race, ethnicity, gender, zip code, medical history, etc. Press the "run calculator" button and the algorithm spits out your odds of testing positive for COVID-19. The Clinic makes clear that their tool is not intended for medical advice.

When I took the survey, I found my risk of getting a positive test was just under 7.5% or about 1 in 13. This is much higher than the odds of being struck by lightening but a lot less than dying of coronary artery disease.

My relatively low level of risk made me curious about how the other factors identified in the Cleveland tool influence risk. I started playing around with the calculator. All other things being equal: what if I were a woman? Lower risk. What if I were Black or Hispanic? Higher risk. This underscores the central point: even though our collective risks are related, your risk is not my risk.

While I can calculate my own risk of contracting COVID-19, I have no way of knowing what yours might be. Only narcissists, fools or villains would dispense with all precautions just because their personal risk is low. What about the other guy?

Were all trying to find ways to live in relative safety. People have got to live their lives, but we can do that and still protect ourselves as well as those around us who are at greater risk from COVID-19. Go ahead and participate in lower-risk activities like cycling, going to the beach and al fresco dining, but think twice about higher risk activities like amusement parks, bar hopping and flying across country.

It is possible to protect your physical health without losing a grip on your mental health. Just dont throw all caution to the wind. By wearing a face covering in public, following the 6-foot rule and washing your hands, you can reduce the risk of infection for everyone.

Ron McAllister is a sociologist and writer who lives in York.

Go here to read the rest:

Assessing the risks: Mine, yours and ours - Foster's Daily Democrat

Immuno-Oncology News recently published results of a Phase 2 clinical trial of the immuno-checkpoint inhibitor Imfinzi (durvalumab) for patients diagnosed with malignant pleural mesothelioma.

The PrECOG cancer research group tested the effects of pairing Imfinzi, an AstraZeneca drug that blocks the activity of the PD-1 receptor in immune T-cells, with standard chemotherapy on a group of 55 individuals who had been recently diagnosed with inoperable malignant pleural mesothelioma. The PD-1/PD-L1 pathway affects inflammation, which causes pleural mesothelioma to develop at a faster rate.

The trial revealed that patients who took Imfinzi in addition to running out courses of standard chemotherapy (pemetrexed with cisplatin or carboplatin) survived for an average of 20.4 months, whereas patients who were given only standard chemotherapy lived for an average of 12.1 months. 81.8 percent of participants were male, their median age was 68, and three-quarters of them had been diagnosed with the epithelioid cancer subtype of malignant pleural mesothelioma.

[Imfinzi] plus standard chemotherapy delivered a promising median overall survival rate for patients with previously untreated, inoperable malignant pleural mesothelioma, affirmed Dr. Patrick Forde, director of the Kimmel Centers thoracic cancer clinical research program, in a news release from the American Society of Clinical Oncology.

AstraZeneca, PrECOG, and the University of Sydney have plans to enroll participants who have been diagnosed with previously untreated, inoperable malignant pleural mesothelioma in a Phase 3 trial in Australia and the United States in September. More details about the upcoming clinical trial can be found here.

If you or a loved one has been diagnosed with mesothelioma, reach out today for a free consultation. Our experts can assist you with medical resources as well as options for compensation from those responsible.

Follow this link:

Clinical Trial of Imfinzi (Durvalumab) in Conjunction with Chemotherapy Yields Significantly Longer Survival Time for Patients Diagnosed with...

HOUSTON, July 23, 2020 /PRNewswire/ --The US Navy Veterans Mesothelioma Advocate says, "If you are a Navy Veteran who has just been diagnosed with mesothelioma in a rural state or their family please call attorney Erik Karst of the law firm of Karst von Oiste anytime at 800-714-0303 to get a serious plan about compensation-that might exceed a million dollars. Erik Karst is one of the nation's leading mesothelioma attorneys and he and his amazing team at Karst von Oiste specialize in assisting Navy Veterans with mesothelioma-and their goal is people like this receive the best possible compensation results." http://www.karstvonoiste.com/

The US Navy Veterans Mesothelioma Advocate fears because of the Coronavirus many Navy Veterans who have mesothelioma will be misdiagnosed with COVID-19-especially in states likeNew York, New Jersey, Illinois, Michigan, California, Pennsylvania, Washington, and North Carolina. As mentioned, mesothelioma compensation might exceed a million dollars-if a Navy Veteran with this rare cancer caused by asbestos exposure receives a confirmed diagnosis.

However, if a Navy Veteran gets misdiagnosed with the Coronavirus as opposed to mesothelioma the chances for compensation are almost zero. If you husband or dad is a Navy Veteran and he had extreme exposure to asbestos in the navy prior to 1982 please be certain to tell the physicians treating him-if he has been diagnosed with the Coronavirus.

The US Navy Veterans Mesothelioma Advocate has endorsed attorney Erik Karst and his amazing colleagues at Karst von Oiste because they have been assisting Navy Veterans and people with mesothelioma for decades and they are responsible for over a billion dollars in compensation results for people like this. For direct access to attorney Erik Karst of the law firm of Karst von Oiste and Navy Veteran with mesothelioma or their family are welcome to call 800-714-0303 anytime.www.karstvonoiste.com/

For a listing of all types of current and past US Navy warships please review the US Navy website on this topic:https://www.navy.mil/navydata/our_ships.asp.

According to the Veterans Administration some of the worst types of asbestos exposure occurred when a US Navy Veteran was stuck on their ship in dry dock or undergoing a major overhaul in shipyard located inWashington,Virginia,Connecticut,California,Maine,Massachusetts,Pennsylvania,New York,Louisiana,HawaiiorGeorgia. https://USNavyMesothelioma.Com

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer. gov/types/mesothelioma.

Media Contact:

Michael Thomas800-714-0303[emailprotected]

SOURCE US Navy Veterans Mesothelioma Advocate

U.S. Navy Veterans Mesothelioma Advocate

View original post here:

US Navy Veterans Mesothelioma Advocate Urges the Family of a Navy Veteran Who Has Mesothelioma in a Rural State to Call Attorney Erik Karst of Karst...

- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients

- Two RECIST unconfirmed partial responses and two patients with stable disease through six months

- Manageable toxicity profile, with only one patient exhibiting TC-210-related non-hematologic Grade >2 toxicity

- Translational data demonstrated T cell expansion and cytokine production

- TCR2 to host conference call today starting at 8:00am E.T. with live webcast available online

CAMBRIDGE, Mass., July 26, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity.

We are delighted that our very first dose of TC-210 induced consistent tumor regression and clinical benefit in heavily pre-treated cancer patients, said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. There are very few options for patients with solid tumors and those expressing mesothelin represent a significant frontier of unmet medical need. While these are early data requiring further study, we are encouraged by the potential of our TRuC-T cells as we continue to enroll and treat patients with the goal of quickly finding a recommended Phase 2 dose for TC-210.

Based on my prior experience working with both TCR-T and CAR-T cells, including the FDA approval of Kymriah, observing consistent clinical benefit in patients at presumably suboptimal T cell doses is quite meaningful, said Alfonso Quints-Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics. These early TC-210 data suggest our approach may overcome the challenges faced by many T cell therapies in the hostile solid tumor microenvironment. Our enrolled patients have failed multiple lines of therapy, including standard chemotherapy, checkpoint inhibitors and in some cases other mesothelin-directed approaches, in indications where survival has been historically shorter than six months.

The primary objectives of the Phase 1 portion of the study are to define the safety profile of TC-210 in patients whose tumors overexpress mesothelin and to determine the recommended Phase 2 dose (RP2D). Secondary objectives include overall response rate (ORR) and disease control rate (DCR). Exploratory objectives include the assessment of expansion, tumor infiltration, and persistence of TC-210 T cells.

Summary of trial conduct, baseline characteristics and TC-210 dose:

Key clinical findings from the first five patients treated with TRuC-T cells include:

About the Phase 1/2 Clinical Trial in Advanced Mesothelin-Expressing Solid Tumors

The Phase 1/2 clinical trial (NCT03907852) is evaluating the safety and efficacy of TC-210, TCR2s T-cell receptor fusion construct directed against mesothelin. The trial is enrolling patients with mesothelin expressing NSCLC, ovarian cancer, cholangiocarcinoma, and malignant pleural/peritoneal mesothelioma. The Phase 1 dose escalation portion of the clinical trial utilizes a modified 3+3 design with four increasing TC-210 T cell doses. At each dose, TC-210 will be tested in two separate dose levels: first without lymphodepletion and then following lymphodepleting chemotherapy. The Phase 1 portion of the clinical trial is ongoing.

In the Phase 2 portion of the clinical trial, approximately 50 patients are planned to receive TC-210 at the RP2D in four distinct cohorts according to their cancer diagnosis: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Each cohort will include ten patients, except the NSCLC cohort which will include 20 patients with eight patients to receive TC-210 as single agent and 12 patients to receive TC-210 in combination with a programmed cell death 1 (PD-1) blocking antibody.

About Mesothelin-Expressing Solid Tumors

Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others. Overexpression of mesothelin is associated with poorer prognosis in some cancers due to its active role in both malignant transformation and tumor aggressiveness by promoting cancer cell proliferation, invasion, and metastasis. Of the wide range of solid tumors expressing mesothelin, non-small cell lung cancer, ovarian cancer, mesothelioma and cholangiocarcinoma represent a significant patient population up to 80,000 in the United States alone.

TCR2 Therapeutics Conference Call and Webcast

TCR2 Therapeutics will host a conference call and webcast on Monday, July 27th at 8:00am E.T. The webcast and presentation will be made available on the TCR2 Therapeutics website in the Investors section under Eventsat http://investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About TCR2 Therapeutics

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Companys lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit http://www.tcr2.com.

Forward-looking Statements

This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of TC-210, future clinical development plans, the development of the Companys TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Companys TRuC-T cell platform.

The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.

Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor and Media Contact:

Carl MauchDirector, Investor Relations and Corporate CommunicationsTCR2 Therapeutics Inc.(617) 949-5667carl.mauch@tcr2.com

View original post here:

TCR Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors - BioSpace

HOUSTON, July 21, 2020 /PRNewswire/ --The Mesothelioma Victims Center says, "We have endorsed attorney Erik Karst of the law firm of Karst von Oiste to ensure a person with mesothelioma receives the best possible financial compensation results-nationwide. For direct access to attorney Erik Karst of Karst von Oiste please call 800-714-0303. One huge complicating factor in mesothelioma compensation in 2020 is the Coronavirus. The Coronavirus and mesothelioma have almost identical symptoms such as pneumonia, high fever, and shortness of breath. As a result, many people who had mesothelioma-have been misdiagnosed with 'possible Coronavirus' and if they died the cause of death probably says-COVID-19. In the event a person with mesothelioma gets misdiagnosed with the Coronavirus and dies-they or their family will probably never see a dime in compensation." http://www.karstvonoiste.com/

The Mesothelioma Victims Center is urging the wife or adult children of a Navy Veteran, a manufacturing, industrial or skilled trades worker, who is over 60 years old and who had significant exposure to asbestos prior to 1982- to please tell his treating physicians about his asbestos exposure if he is now in the hospital with what they are calling possible 'Coronavirus-COVID-19.' The average age for a person with mesothelioma in the United States is about 72 years old. https://MesotheliomaVictimsCenter.Com

The reason the Mesothelioma Victims Center has endorsed attorney Erik Karst of the law firm of Karst von Oiste is because he and his colleagues have been assisting Navy Veterans and people with mesothelioma for decades and they are responsible for over a billion dollars in financial compensation for people like this. For direct access to attorney Erik Karst of Karst von Oiste please call 800-714-0303. "Please do not roll the dice on mesothelioma compensation in 2020. Erik Karst is one of the nation's leading mesothelioma attorneys and he is an amazing resource."www.karstvonoiste.com/

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. http://www.karstvonoiste.com/

High risk work groups for exposure to asbestos include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, manufacturing, or industrial workers, plumbers, electricians, auto mechanics, machinists, miners, or construction workers. Typically, the exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. https://MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma.

Media Contact:

Michael Thomas800-714-0303240829@email4pr.com

See more here:

Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst von Oiste to Ensure a Person Who Turned Out to Have Mesothelioma After Initially...

Published on July 17, 2020

The city of Auckland in New Zealand is experiencing unprecedented economic expansion, but the new construction going on to accommodate that growth may be putting the population at risk for malignant mesothelioma. A recent article in theNew Zealand Medical Journalhas reported that the volcanic bedrock under the city contains erionite, an asbestos-like mineral that when inhaled may cause the rare and fatal form of cancer.

Workers are excavating volcanic rock to build a tunnel that will connect existing train lines and platforms beneath the Britomart Train Station, and this has raised concerns from the papers authors that construction workers and those in the vicinity of the project may be at risk for malignant mesothelioma. They worry that dust raised by the work will be filled with a potentially carcinogenic material.

According to University of Auckland associate professor Martin Brook, the rock bed under the train station may contain erionite, a mineral made from volcanic ash that eventually forms a fibrous rock much like asbestos. Breathing in erionites dust and particles creates an effect similar to that of asbestos, and speaking of the need to determine whether the toxic substance is present and to study its impact further, Brook said, Currently there are no international or New Zealand occupational exposure limits or standard low-cost field sampling and analytical methods for erionite.

Though the University of Auckland scientists have not definitively stated that erionite causes mesothelioma, they point to previous studies showing that in locales where erionite has been disturbed, malignant mesothelioma rates have increased decades later. Associate professor and co-author of the study Jennifer Salmond said, This lag between dose and response makes it very difficult to know when, where, or how much erionite people might have been exposed to prior to getting ill.

To date the group has indicated that construction workers and quarry workers are most at risk, and they are urging further study to determine whether erionite is present in areas where construction is planned. In the Auckland region we need to know where this mineral is and how much is present in soils and air before we can quantify the risk it presents to both occupational and public health.

In the United States, most cases of mesothelioma are caused by asbestos-contaminated products for which appropriate protection and warnings were not provided. For information on resources available to mesothelioma victims, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.

Learn more about and contact Terri

See more here:

New Zealand Scientists Warn of Mesothelioma Risk from Construction Projects - Mesothelioma.net Blog

Researchers and medical experts often compare pleural mesothelioma and peritoneal mesothelioma. One of the most striking differences? Prognosis, as peritoneal mesothelioma carries much better odds of prolonged survival.

Most peritoneal survival stories involve one consistency: aggressive surgery, which a recent study confirmed.

The Annals of Surgical Oncology published a report that includes analysis of peritoneal mesothelioma survival trends. The focus is on survival after aggressive, potentially life-saving surgery compared to survival without surgery.

The results showed a staggering yet unsurprising difference. Its the strongest evidence in support of newly diagnosed peritoneal mesothelioma patients undergoing surgery right away.

The primary surgery for peritoneal mesothelioma is cytoreduction. This operation involves debulking, or physically removing all visible tumors from the disease area. Surgeons also perform a peritonectomy, which requires removing the thin lining where this cancer forms.

This lining, called the peritoneum, wraps around your abdominal cavity. It includes two walls of mesothelial cells. Their primary function is to protect essential cavities and organs in the abdomen. While helpful, this lining is not critical to continued good health or high quality of life.

Following cytoreduction, most peritoneal mesothelioma patients undergo hyperthermic (heated) intraperitoneal chemotherapy. This therapy, shortened to the acronym HIPEC, involves bathing the abdomen in warm liquid chemotherapy drugs. The treatment addresses remaining tumors in the abdomen and reduces the chances of mesothelioma recurrence.

Cytoreduction with HIPEC lasts 8-14 hours, depending on the extent of the cancer. Patients remain in inpatient care for 10-12 days following the procedure.

From 2003-2014, the National Cancer Database registered 2,062 malignant peritoneal mesothelioma cases. The term malignant means the case is cancerous and actively spreading.

Of those 2,062 patients:

Using systemic chemotherapy after cytoreduction with HIPEC improved the median mesothelioma survival to 41.8 months.

These statistics are not new revelations. For years, peritoneal mesothelioma specialists have vouched for cytoreduction with HIPEC. In an older study, around 55% of cytoreduction with HIPEC patients survived for at least three years.

Mesothelioma Guide has documented numerous survivor stories from peritoneal mesothelioma:

As the stats show, others have survived peritoneal mesothelioma thanks to aggressive surgery. We at Mesothelioma Guide can refer you to other mesothelioma survival stories. If you have peritoneal mesothelioma, then we can help you become the next story of hope.

Reach out to our patient advocate and registered nurse, Jenna Campagna, to get a list of all cancer centers and doctors that perform peritoneal mesothelioma surgery. Please email her at jenna@mesotheliomaguide.com whenever youre ready.

Show Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

Read more from the original source:

Research Shows Why You Should Have Peritoneal Mesothelioma Surgery - Mesothelioma Guide

NEW YORK After four years and two trials, former New York Assembly Speaker Sheldon Silver was sentenced Monday to 6 years for a corruption scheme involving developers dependent on Albany support.

Silver, 76, had last been sentenced to seven years in prison for the developers scheme, as well as a second involving legal referrals for mesothelioma patients. The 2nd Circuit Court of Appeals tossed the guilty verdicts tied to the latter scam in January and ordered Silver be resentenced.

The Lower East Side Democrat was convicted of secretly taking $800,000 in legal fees from real estate developers from 2005 to 2015. The money came mainly from Glenwood Management, which owns luxury apartment buildings in Manhattan and the Bronx. The company is one of the biggest campaign contributors in state politics.

In return for the money, Silver performed a number of favors, including supporting tax breaks and landlord-friendly rent rules under the states 2011 Rent Act and voting in favor of Glenwoods applications for tax-exempt financing of its projects.

Silver, once one of the three men in a room who decided major New York State policies in secret, begged Judge Valerie Caproni for leniency in a letter in June.

Your Honor, I do not want to die in prison, pleaded Silver, who was Assembly speaker from 1994 to 2015.

As a public official, you are not entitled to anything. You have to earn your votes every day and your rewards are in the satisfaction that you did good and earned the respect of the community, which are both deeply meaningful. This has to be enough, otherwise find a new line of work.

It should have been enough for me but it wasnt and I am ruined.

Silver was found guilty twice of a second corruption scheme involving $3.3 million earned through legal referrals of mesothelioma patients. The 2nd Circuit Court of Appeals vacated three charges related to that scheme, ruling that it did not meet the legal standards for extortion.

Silver was first sentenced to 12 years in prison for the schemes in May 2016. A Supreme Court ruling that changed the legal definition of public corruption required he be tried again.

Caproni has noted that Silver aged dramatically during the long legal fight.

Visually, hes aged more than the three years chronologically that have gone by since he was first charged, she said in 2018.

Excerpt from:

Former state Assembly speaker Sheldon Silver sentenced to more than 6 years in prison - NNY360

TRIBUNE NEWS SERVICEFormer speaker of the New York State Assembly, Sheldon Silver enters federal court in New York on the first day of his second trial on April 30, 2018.

By Stephen Rex BrownNew York Daily NewsNEW YORK After four years and two trials, former New York Assembly Speaker Sheldon Silver was sentenced Monday to 6 1/2 years for a corruption scheme involving developers dependent on Albany support.Silver, 76, had last been sentenced to seven years in prison for the developers scheme, as well as a second involving legal referrals for mesothelioma patients. The 2nd Circuit Court of Appeals tossed the guilty verdicts tied to the latter scam in January and ordered Silver be resentenced.The Lower East Side Democrat was convicted of secretly taking $800,000 in legal fees from real estate developers from 2005 to 2015. The money came mainly from Glenwood Management, which owns luxury apartment buildings in Manhattan and the Bronx. The company is one of the biggest campaign contributors in state politics.In return for the money, Silver performed a number of favors, including supporting tax breaks and landlord-friendly rent rules under the states 2011 Rent Act and voting in favor of Glenwoods applications for tax-exempt financing of its projects.Silver, once one of the three men in a room who decided major New York state policies in secret, begged Judge Valerie Caproni for leniency in a letter in June.Your Honor, I do not want to die in prison, pleaded Silver, who was Assembly speaker from 1994 to 2015.As a public official, you are not entitled to anything. You have to earn your votes every day and your rewards are in the satisfaction that you did good and earned the respect of the community, which are both deeply meaningful. This has to be enough, otherwise find a new line of work.It should have been enough for me but it wasnt and I am ruined.Silver was found guilty twice of a second corruption scheme involving $3.3 million earned through legal referrals of mesothelioma patients. The 2nd Circuit Court of Appeals vacated three charges related to that scheme, ruling that it did not meet the legal standards for extortion.Silver was first sentenced to 12 years in prison for the schemes in May 2016. A Supreme Court ruling that changed the legal definition of public corruption required he be tried again.Caproni has noted that Silver aged dramatically during the long legal fight.Visually, hes aged more than the three years chronologically that have gone by since he was first charged, she said in 2018.

Continued here:

Ex-NY Assembly speaker gets 6 1/2 years in prison - The Recorder

The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. Theglobal cancer therapeutics marketsize was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.

Request For Report[emailprotected]https://www.trendsmarketresearch.com/report/sample/13204

Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.

However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market. Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry. An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning. The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/13204

KEY MARKET SEGMENTS

By Applicationo Blood Cancero Lung Cancero Colorectal Cancero Prostate Cancero Breast Cancero Cervical Cancero Head and Neck Cancero Glioblastomao Malignant Meningiomao Mesotheliomao Melanomao Others

By Top Selling Drugso Revlimido Avastino Herceptino Rituxano Opdivoo Gleeveco Velcadeo Imbruvicao Ibranceo Zytigao Alimtao Xtandio Tarcevao Perjetao Temodaro Others

By Regiono North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia-Pacific Japan China India Australia South Korea Taiwan Rest of Asia-Pacifico LAMEA Latin America Middle-East Africa

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/13204

The list of key players operating in this market include: F. Hoffmann-La Roche AG Bristol-Myers Squibb Company AbbVie, Inc. Johnson & Johnson Celgene Corporation Astellas Pharma, Inc. Pfizer, Inc. Novartis AG Merck KGaA Eli Lilly and Company

The other players included in the value chain analysis (and not included in the report) include: AstraZeneca plc Bayer AG Takeda Pharmaceutical Company Limited

Read the original here:

Cancer Therapeutics Market Impact Of Covid-19 And Benchmarking - Cole of Duty

Mesothelioma: What Is Malignant Mesothelioma Cancer?

Alert: We're here for you. Learn how COVID-19 may affect mesothelioma patients.

Mesothelioma is a malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen or heart. Symptoms can include shortness of breath and chest pain. The life expectancy for most mesothelioma patients is approximately 12 months after diagnosis. Treatment may improve prognosis and can include surgery, chemotherapy or radiation.

Learn more about mesothelioma and the steps you can take to fight this disease.

Mesothelioma is an incurable, asbestos-related cancer that typically affects the lining of the lungs. However, mesothelioma tumors can develop in the lining of the abdominal cavity or heart.

Key Facts about Mesothelioma

Symptoms of mesothelioma appear when tumors spread, grow and press against the chest wall and the abdominal cavity. Chest pain and shortness of breath are the most common symptoms.

A balanced mesothelioma diet can help ease your symptoms and speed recovery. Get a free nutrition guide with quick and easy recipes that can help improve your quality of life.

A biopsy is the only mesothelioma test that confirms a diagnosis. Doctors may use additional diagnostic procedures. An early mesothelioma diagnosis may increase a patients eligibility for all treatment options.

Most people initially undergo a basic chest X-ray to check for any abnormalities. If an abnormal growth or fluid around the lung is detected, doctors will recommend a more detailed imaging scan such as a PET scan, CT scan or MRI.

If cancer is suspected, doctors will recommend taking a sample of tissue, also knowns as a biopsy. Doctors use this tissue sample to definitively confirm the presence of malignant mesothelioma cells.

Blood tests may be used but do not confirm the presence of mesothelioma. Researchers are evaluating if blood tests can aid in the early diagnosis of at-risk former asbestos workers.

Doctors use at least five staging systems to stage pleural mesothelioma. The IMIG staging system is preferred. No universal staging system exists for the other mesothelioma types.

Asbestos exposure is the primary cause of mesothelioma. People exposed to asbestos at home, work or in the military have a higher risk of developing the cancerous disease.

A person inhales or swallows microscopic airborne asbestos fibers.

The asbestos fibers become lodged in the lining of the lungs, abdomen or heart.

Embedded fibers damage mesothelial cells and cause inflammation.

Over time, tumors form on the damaged mesothelium, leading to mesothelioma.

People most at risk of developing mesothelioma handled asbestos for a prolonged period of time or were exposed to large amounts of asbestos as part of their career.

Secondhand exposure is also common, especially among the spouses and children of people who worked with asbestos.

Firefighters, construction workers, power plant workers, shipyard workers and others are among these types of workers.

U.S. Navy veterans are most at risk. Army, Marine Corps, Air Force and Coast Guard veterans also face health risks.

Spouses, children and others who lived with a person who was regularly exposed to asbestos fibers are at risk.

Experienced mesothelioma attorneys will help you get compensation for treatment costs, lost wages and other expenses.

The stages of mesothelioma range from 1 to 4 and are based on tumor size and location.

Early-stage mesothelioma is usually more confined to one site, while late-stage mesothelioma shows tumors spreading beyond the chest or abdominal cavity. Staging is an important part of determining treatment.

The cancer is localized. Surgery is most effective at this stage. Survival rate is higher. A patients median life expectancy at stage 1 is 22.2 months.

Tumors have spread from the original location and moved into adjacent structures. Surgery is still an option. Median life expectancy at stage 2 is 20 months.

Cancer has spread into the regional lymph nodes. Surgery is an option in select circumstances. The patients median life expectancy at stage 3 is 17.9 months.

Tumors have spread into distant organs. Chemotherapy and immunotherapy ease symptoms. Median life expectancy at stage 4 is 14.9 months.

The four types of mesothelioma cancer are identified by the location in the body where tumors develop. Pleural and peritoneal types of mesothelioma are the most common. Pericardial mesothelioma accounts for 1% of cases.

Prognosis, symptoms and treatment options vary by mesothelioma type.

There are three cell types of mesothelioma named for the cancerous cells found in the tumors: Epithelioid, sarcomatoid and biphasic. Some are more common and respond well to treatments. Others are rarer and more resistant to therapies.

These cells are the most responsive to treatment. This type of mesothelioma accounts for 70% of mesothelioma diagnoses. It also leads to improved prognosis and life expectancy.

Cells of this type are least responsive to treatment. Patients with these cell types have poorer diagnoses and shorter life expectancies. This mesothelioma type accounts for 10% of all cases.

This is a combination of epithelioid and sarcomatoid cells. Its less responsive to treatment. Prognosis and life expectancy depend on the ratio of both cell types. It accounts for 30% to 40% of cases.

Mesothelioma cancer is treated with conventional therapies such as surgery, chemotherapy and radiation. But not every patient is eligible for each type of mesothelioma treatment. Some patients also opt for emerging cancer treatments, including clinical trials, and alternative therapies.

This therapy is used for diagnosing, removing tumors or easing pain. It offers the greatest chance of survival for patients with strong health and limited cancer spread.

More than 70% of patients undergo chemotherapy. The therapys strong drugs shrink tumors and kill cancer cells, but it also presents severe treatment side effects.

The therapy can be used at any cancer stage. Doctors perform it to reduce pain and slow tumor growth. It is often combined with surgery and chemotherapy.

Researchers and doctors offer these experimental therapies across the nation to eligible patients. Clinical trials lead to new or improved treatments.

Most doctors have never encountered mesothelioma because it is a rare cancer. Doctors who focus on mesothelioma at specialty treatment centers provide patients the best chances of extending life and improving prognosis.

In fact, a 2009 Journal of General Internal Medicine study showed cancer care requires skills of specialty physicians such as medical oncologists, surgeons and radiation oncologists.

Mesothelioma specialists encompass a number of specialties, including surgery, medical and radiation oncology, radiology, pathology and palliative care. All can be part of a patients treatment plan. Working with an experienced mesothelioma doctor can make all the difference.

The most-regarded treatment centers attract people from across the country. Renowned for their cutting-edge technology and groundbreaking research, these centers can connect you with a multidisciplinary team of physicians with years of experience in treating asbestos-related diseases.

Research, get a second opinion from a mesothelioma specialist and dont be afraid to ask questions. You cant make an informed decision if you dont have the information.

Emily Ward

Pleural Mesothelioma Survivor

The prognosis for mesothelioma is not good. The life expectancy for most patients is about 12 months after diagnosis. Those who can undergo multimodal therapy, which is a combination of two or more treatments, have an improved prognosis.

Factors that most affect mesothelioma prognosis are stage and cell type. Age, gender and exposure history also affect outlook. Younger patients and women have a better mesothelioma prognosis than older men. People diagnosed with the peritoneal mesothelioma type also have a higher chance of survival.

Patients can improve prognosis by eating a nutrient-rich diet, staying healthy, undergoing cancer treatments and making healthier lifestyle choices such as quitting smoking.

Legal and financial options for mesothelioma patients and their families can provide financial compensation to pay medical bills, cover lost wages and other expenses. A mesothelioma lawyer can review your case, so you receive the highest compensation.

A mesothelioma patient can file a personal injury lawsuit. The estate of the patient who died from mesothelioma can file a wrongful death lawsuit.

Bankrupt asbestos companies established trust funds to provide compensation for people exposed to asbestos because of company negligence.

Because the U.S. military relied heavily on asbestos, veterans diagnosed with mesothelioma may be eligible for financial and medical benefits.

Many forms of support are available for mesothelioma patients, survivors, loved ones and families.

Mesothelioma survivors, caregivers and family members often need a place where they can share their ongoing struggles and amazing accomplishments. We offer a support group, hosted by a licensed mental health counselor, that offers a safe place for all mesothelioma survivors.

You and your loved ones can advocate for others who are going through the same cancer journey. Getting involved in the move to ban asbestos and raise mesothelioma awareness can have long-lasting and positive effects.

Request a comprehensive mesothelioma guide to gain a deeper understanding of the cancer and how you can help your loved one during this difficult time. We can provide you with a free must-read book that answers frequently asked questions about mesothelioma.

Our latest guide for patients and loved ones is shipped overnight and includes treatment information, legal resources, mesothelioma books and support wristbands.

Common Questions About Mesothelioma

Read more here:

Mesothelioma: What Is Malignant Mesothelioma Cancer?

The COVID-19 virus has disrupted all of our lives and routines. Things that we always did and places we always went are no longer available. The pandemic has forced us to all look at things we routinely do and challenged us to do them differently.

Like in business, in medicine sometimes small disruptions can lead to larger innovative changes. In the treatment of malignant mesothelioma, disruptors have led the way. Over the years we have seen doctors challenging the previously held belief that there was no treatment for malignant mesothelioma time and time again. The treatment options and longer quality of life that many mesothelioma patients are now able to be part of was not an option 20 years ago.

Before the pandemic, having a doctors visit for the vast majority of people involved going to the office or clinic at an appointed time, waiting, and meeting with the doctor. Patients diagnosed with malignant mesothelioma had the option of travelling to a Mesothelioma Center of Excellence to consult with experts in the field. Since the pandemic, with social isolation and doctors offices and clinics closed to prevent the spread of the virus, there has been a surge of tele-health visits.

The U.S. Department of Health and Human Services Office for the Advancement of Telehealth promotes the use of telehealth technology for health care. Their definition of tele-health is the use of electronic information and telecommunications technologies to support and promote long-distance clinical health care, patient and professional health-related education, public health and health administration. Technologies include videoconferencing, the internet, store-and-forward imaging, streaming media, and terrestrial and wireless communications.

In 2018, tele-health was 0.1 percent of all medical claims filed. Since the pandemic those numbers are exploding.

Tele-health has made possible consults and reviewing of scans and meetings with mesothelioma experts. As things are starting to open back up, so are the patients coming back to the mesothelioma centers for in-person consultations.

Like any new technology telehealth has pros and cons. Some people have commented that you have the MDs full attention without the distractions of an office and other responsibilities. Other people have missed the personal interaction and meeting in person with their doctor.

The coronavirus has brought to the forefront a technology that can benefit a lot of people as they search for the best advanced personalized care for themselves or loved ones with mesothelioma. Tele-health can help malignant mesothelioma patients connect with a mesothelioma center without having to travel. It will take awhile to assess how tele-health will be accessed and have the best results for patients. For patients, their satisfaction with tele-health will need to be studied and evaluated to continue to efficiently access tele-health with the best results.

If you or a family member is diagnosed with malignant mesothelioma reach out, either electronically or in person for the best possible care. Our experts can help connect you with both the medical and legal resources you need to move forward.

See the original post:

Mesothelioma Patients Can Safely Get Treatment Through Telehealth and Video - MesotheliomaHelp.org

We continue to monitor how various courts in California are handling asbestos trials. The situation is unsurprisingly fluid. Some courts have started trials and we are closely following those.

San Francisco assigned one case to a trial judge on June 26, 2020. Discussions of how that matter would proceed to trial were ongoing when the case resolved. Generally, remote jury selection was discussed. There were discussions about how to have the jurors in court socially distanced and having virtually all witnesses appear remotely.

In Alameda County (Oakland), jury selection is ongoing in two cases. These are both living mesothelioma cases with preference trial dates. Both cases had been initially set for trial in March. Jury selection is being conducted remotely with hardships and questionnaires done electronically and voir dire via Zoom. Both cases appear headed to a situation where the jurors are participating 100% remotely unless they do not have the technical ability to do so. It appears that all witnesses will appear remotely. Defendants have raised significant due process concerns, and in one case petitioned the Court of Appeal for a writ. The Court of Appeal denied the petition as premature, even while acknowledging that serious fairness issues were being raised.

Los Angeles County does not have any jurors available yet, but has just started re-issuing jury summonses. It is anticipated that all of the first wave of jurors will go to criminal cases. There are several preference cases pending trial that are being continued on a rolling 15-day basis (per the preference statute) until a jury pool is available. The court has urged parties to waive a jury (neither side has agreed) or consider smaller jury panels. The court is setting new preference trial dates in the fall, but noting that those trial dates are not realistic and the cases will likely be continued until there are juries available.

Low priority cases such as wrongful death cases and non-preference personal injury cases are being continued into 2021 in all three venues. When and how the courts will catch up on those remains to be seen.

All three of Californias primary asbestos courts are utilizing the MSC process to try to facilitate resolution of cases. Los Angeles and Oakland are ordering remote MSCs. San Francisco required counsel to appear in person. None of these courts are requiring client or carrier representatives to travel to appear in person.

Courts with very few cases (Fresno, Sacramento, Solano, etc.) do not seem to be treating asbestos cases any different than any other casesmeaning we do not anticipate trials before 2021.

Federal courts generally remain in operation but jury trials seem to be limited to criminal cases only. We are not aware of any Federal asbestos cases being called to start jury trials since the pandemic shut court operations down.

More:

California Asbestos Trials in the Age of COVID-19 - Lexology

Published on July 14, 2020

Page Last Modified: July 17, 2020

In May of 2019, the U.S. Food and Drug Administration approved the NovoTTF-100L System for the treatment of unresectable malignant pleural mesothelioma. Just over one year later, Novocure, the devices manufacturer, has announced that over 100 physicians from more than 50 different cancer centers across the United States are now certified to prescribe use of the device in combination with pemetrexed plus platinum-based chemotherapy.

Originally called the Novocure TTF-100L the device for treatment of mesothelioma patients whose tumors are beyond the reach of surgery was renamed Optune Lua.Physicians treating patients diagnosed with the rare and fatal form of cancer have expressed great hope for its effectiveness and ability to extend and improve patients lives.

Mesothelioma is a condition that has proven particularly challenging to treat, explained Mathew T. Ballo, M.D., FACR, Professor and Chair, Department of Radiation Oncology, West Cancer Center & Research Institute in Germantown, Tennessee. The FDAs approval of this new technology has been met with significant enthusiasm from specialists in the disease.This is a disease with a poor prognosis, so being able to offer patients a therapy that results in excellent response rates with minimal toxicity is exciting, he said. We as clinicians can have a big impact on our patients lives by making them aware of this important new technology.

Novocures innovative technology development uses electric fields to interrupt cell division, thus stopping tumors from growing and eventually leading to their death. Its approval in the treatment of malignant mesothelioma represents the first treatment to garner approval from the FDA since the combination of pemetrexed and cisplatin in 2004.

In addition to treating malignant mesothelioma, the device has also been approved for treatment of glioblastoma, and its effectiveness is also being explored for the treatment ofother solid tumors, includingbrain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.

If you or someone you love has been diagnosed with malignant mesothelioma and you need information about innovative treatments, the Patient Advocates at Mesothelioma.net can help. Contact us today at 1-800-692-8608.

Learn more about and contact Terri

Read the original post:

More Than 100 Physicians Now Certified to Prescribe Tumor Treating Fields for Mesothelioma - Mesothelioma.net Blog